Related Experiment Video
Updated: Aug 5, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.8K
A Pilot Study Exploiting the Industrialization Potential of Solid Lipid Nanoparticle-Based Metered-Dose Inhalers
Lei Shu1, Wenhua Wang2, Chon-Iong Ng1
1College of Pharmacy, Jinan University, Guangzhou 510006, China.
Pharmaceutics
|March 29, 2023
Summary
This study developed nanocoated solid lipid nanoparticles (SLN) for metered-dose inhalers (MDI) to treat lung diseases. The scalable SLN-based MDI formulations demonstrated good reproducibility and stability, paving the way for advanced inhalable therapies.
Area of Science:
- Nanotechnology and Pharmaceutical Sciences
- Drug Delivery Systems
- Inhalable Nanoparticle Engineering
Background:
- Metered-dose inhalers (MDI) offer a promising route for delivering inhalable nanoparticles to treat lung diseases like asthma and COPD.
- Nanocoating enhances nanoparticle stability and cellular uptake but complicates manufacturing, necessitating streamlined production methods for clinical translation.
Purpose of the Study:
- To explore the industrialization potential of solid lipid nanoparticles (SLN) encapsulated in MDIs for enhanced lung disease treatment.
- To develop and characterize nanocoated SLN with specific functionalities (stabilization, cellular uptake enhancement, targetability) for MDI delivery.
Main Methods:
- Solid lipid nanoparticles (SLN) were engineered using a reverse microemulsion strategy.
- Three nanocoating types were applied: Poloxamer 188 (SLN(0)), cetyltrimethylammonium bromide (SLN(+)), and hyaluronic acid (SLN(-)).
- SLN were loaded into MDIs, and their processing reliability, physicochemical properties, formulation stability, and biocompatibility were assessed.
Main Results:
- Successfully fabricated three types of SLN-based MDI formulations with excellent reproducibility and stability.
- SLN(0) and SLN(-) formulations exhibited negligible cytotoxicity, indicating good biocompatibility.
- Characterization confirmed successful nanocoating and particle property modulation.
Conclusions:
- This study provides a foundational pilot for scaling up SLN-based MDI production.
- The developed nanocoated SLN-MDI systems hold potential for future advancements in inhalable nanoparticle-based therapeutics for lung conditions.
